The log-rank test showed that patients with high PTPN1 expression had significantly worse DSS in BLCA, GBM, HNSC, KICH, KIRC, LGG, LIHC, MESO, OV, PAAD, SARC, THCA, and UVM, while a significantly longer DSS was observed in BRCA, CESC, KIRP, LUAD, and SKCM (Supplementary Figure S1). This evidence concerns the gene PTPN1 and bladder transitional cell carcinoma.